Cost-effectiveness of oral fingolimod and intramuscular interferon-beta 1a for relapsing remitting multiple sclerosis (RRMS): Results based on efficacy inputs from a head-to-head study

Authors
Category Primary study
JournalJournal of Managed Care Pharmacy
Year 2011
This article has no abstract
Epistemonikos ID: 9191ebed63b66f153201603ba1b06bc9d0bbbed7
First added on: Feb 05, 2025